Neuroscience of Marijuana Impaired Driving

Marijuana Impairment Clinical Trial

— MJDriving  

Official title:

Neuroscience of Marijuana Impaired Driving

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02757313
• Other study ID #: 1507016175
• Secondary ID: 1R01DA038807-01A
• Status: Completed
• Phase: Phase 1
• Start date: October 2016
• Est. completion date: May 2021

Study information

• Verified date: June 2022
• Source: Yale University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Marijuana is one of the most widely used substances. However, marijuana intoxication is not fully understood in relation to driving. This study will help the investigators learn more about the potential impairments related to marijuana intoxicated driving. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure intoxication and impairment. This study will also assess levels of marijuana in blood and saliva samples. This study takes place in Hartford, Connecticut.

Description:

Cannabis is a commonly abused drug whose use cuts across social class, is linked to cognitive impairment, and may be a major contributor to intoxication-related accidents - either alone or with alcohol. However, cannabis intoxication is little studied in relation to driving compared to alcohol. Not only does the current NHTSA Strategic Plan for Behavioral Research prioritize understanding how drugs other than alcohol contribute to traffic crashes, it has recently become more pressing to understand the effects of cannabis because of increasing rates of legalized medical and/or recreational use, that will likely result in more cannabis intoxicated drivers. Social and legal policy will be unable to effectively address the many concerns about driving safety raised by more frequent and widespread use of cannabis without new research to better determine the parameters within which cannabis use does, or does not, increase automobile accident risk. The purpose of this study is to better describe specific, driving-related cognitive impairments caused by acute cannabis intoxication, their persistence over time, underlying functional brain anatomy, and relationship to performance on a state-of the art validated simulated driving task in which the investigators have prior experience. In a randomized, counterbalanced, double-blinded fashion, the investigators will administer two cannabis doses and placebo of smoked cannabis (paced inhalation using a vaporizer) to 48 regular cannabis users and 48 occasional cannabis users on 3 separate occasions. Following cannabis dosing cognitive and driving impairment will be assessed longitudinally for several hours using a combination of fMRI and neuropsychological tests, to clarify relationships between subjective and objective measures of intoxication and of impairment, that include expert assessment of THC and its metabolite levels in blood and saliva. This study takes place in Hartford, Connecticut.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: May 2021
• Est. primary completion date: May 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Must have a current driver's license
• Have used marijuana before
• Right handed

Exclusion Criteria:

• Females who are pregnant or breast feeding
• Unable or unsafe to have an MRI
• Any serious medical, or neurological disorder
• Any psychiatric disorder
• No major head traumas

Related Conditions & MeSH terms

• Marijuana Abuse
• Marijuana Impairment

Intervention

Drug:
• Low dose THC marijuana

• High dose THC marijuana

• Placebo marijuana

Locations

Country	Name	City	State
United States	Olin Neuropsychiatry Research Center	Hartford	Connecticut

Sponsors (6)

Lead Sponsor	Collaborator
Yale University	Hartford Hospital, Maastricht University, Montana State University, National Institute on Drug Abuse (NIDA), The Mind Research Network

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in performance on fMRI simulated driving Gap Acceptance Task	The Gap Acceptance Task measures strategic control of the vehicle. Strategic control of the vehicle is measured by size of headway gaps that the participant chooses in pulling out into a stream of traffic.	Post drug administration at: 30 min, 3 hours and 5.25 hours
Primary	Change in performance on fMRI simulated driving Road Tracking Task.	The Road Tracking Task measures operational control of the vehicle. Operational control is measured by standard deviation of lane position from the center point of the lane.	Post drug administration at: 30 min, 3 hours and 5.25 hours
Primary	Change in performance on fMRI simulated driving Car Following Task.	The Car Following Task measures tactical control of the vehicle. Tactical control of the vehicle is measured by following distance from a lead vehicle.	Post drug administration at: 30 min, 3 hours and 5.25 hours
Primary	Change in concentration of THC/metabolites in oral fluid tested using Draeger Drug Detection Kits	Saliva samples will be taken at 8 total time points throughout the day using the Draeger Drug Detection kits to assess for changes in concentration of THC and its metabolites.	Baseline and post drug administration at: 5 min, 20 min, 1 hr 10 min, 1 hr 45 min, 2 hrs 30 min, 4 hrs, and 6 hrs 30 min,
Primary	Change in concentration of THC/metabolites in oral fluid tested using Quantisal Oral Fluid Collection devices.	Saliva samples will be taken at 8 total time points throughout the day using the Quantisal Oral Fluid Collection devices to assess for changes in concentration of THC and its metabolites.	Baseline and post drug administration at: 5 min, 20 min, 1 hr 10 min, 1 hr 45 min, 2 hrs 30 min, 4 hrs, and 6 hrs 30 min,
Primary	Change in concentration of THC/metabolites in blood samples.	Blood samples will be taken at 8 total time points throughout the day to assess for changes in concentration of THC and its metabolites.	Baseline and post drug administration at: 5 min, 20 min, 1 hr 10 min, 1 hr 45 min, 2 hrs 30 min, 4 hrs, and 6 hrs 30 min,
Primary	Marijuana performance changes on the Critical Tracking Task.	The Critical Tracking Task assesses visuomotor tracking, it will be administered prior to dosing and at various time points after dosing.	Post drug administration at two of the following time points (which varies dependent on the visit day): 2 hours; 4.25 hours; 6.5 hours
Primary	Marijuana performance changes on the Tower of London task.	The Tower of London is a task that assesses executive functioning, it will be administered prior to dosing and at various time points after dosing.	Post drug administration at two of the following time points (which varies dependent on the visit day): 2 hours; 4.25 hours; 6.5 hours
Primary	Marijuana performance changes on the Cogstate 1-back/2-back task.	The Cogstate 1-back/2-back task assesses working memory, it will be administered prior to dosing and at various time points after dosing.	Post drug administration at two of the following time points (which varies dependent on the visit day): 2 hours; 4.25 hours; 6.5 hours
Primary	Marijuana performance changes on the Cogstate Detection Task.	The Cogstate Detection Task assesses processing speed, it will be administered prior to dosing and at various time points after dosing.	Post drug administration at two of the following time points (which varies dependent on the visit day): 2 hours; 4.25 hours; 6.5 hours
Primary	Marijuana performance changes on the Cogstate Set Shifting Task.	The Cogstate Set Shifting Task assesses executive functioning, it will be administered prior to dosing and at various time points after dosing.	Post drug administration at two of the following time points (which varies dependent on the visit day): 2 hours; 4.25 hours; 6.5 hours
Secondary	Change in performance on fMRI Set-Shifting paradigm.	The set shifting paradigm measures attentional and executive domains.	Post drug administration at: 1.25 hours, 3.5 hours and 6 hours
Secondary	Change in performance on fMRI Time Estimation paradigm.	The time estimation paradigm measures misjudgment of time intervals based on participant responses indicating whether one time interval was the same, longer or shorter than the previous time interval.	Post drug administration at: 1.25 hours, 3.5 hours and 6 hours